Illiano, Stephane
Poirier, Bruno
Minoletti, Claire
Pasquier, Olivier
Riva, Laurence
Chenede, Xavier
Menguy, Isabelle
Guillotel, Michel
Prigent, Philippe
Le Claire, Stéphane
Gillot, Florence
Thill, Gilbert
Lo Presti, François
Corbier, Alain
Le Bail, Jean-Christophe
Grailhe, Patrick
Monteagudo, Edith
Ingenito, Raffaele
Bianchi, Elisabetta
Philippo, Christophe
Duclos, Olivier
Mallart, Sergio
Bathgate, Ross
Janiak, Philip
Funding for this research was provided by:
National Health and Medical Research Council of Australia Research Fellowship (1135837)
Article History
Received: 12 July 2022
Accepted: 18 November 2022
First Online: 28 November 2022
Competing interests
: S. Illiano, B. Poirier, C. Minoletti, L. Riva, X.Chenede, I. Menguy, M. Guillotel, P. Prigent, S. Le-Claire , F. Gillot, G. Thill, F. Lo Presti, A. Corbier, JC Le Bail , P Grailhe , O. Pasquier, Christophe Philippo, O. Duclos, S. Mallart, P. Janiak are employees of Sanofi. E. Monteagudo, R. Ingenito, E. Bianchi, are employees of IRBM. S. Illiano, C. Minoletti, O. Duclos, S. Mallart R. Ingenito, E. Bianchi are inventor on patents on related B chain peptides (0233495.A1 Modified relaxin B Chain peptides and their therapeutic use and 0233493 A1, Modified lipidated relaxin B Chain peptides and their therapeutic use). R. Bathgate is an inventor on a patent on related relaxin B chain peptides (10081662 B2, Modified Relaxin B chain peptides).